Our board members
Luis Martinez, M.D., MPH
President, XanoGene Clinic
San Juan, Puerto Rico
Co-Founder, Clinical Peptide Society
Founder Senotherapeutic Network
President, XanoGene Clinic
San Juan, Puerto Rico
Co-Founder, Clinical Peptide Society
Founder Senotherapeutic Network
Dr. Luis Martínez is a Regenerative Medicine, Anti-aging and Cell Therapy specialist, clinical researcher and biomedical consultant. He earned his medical degree at The Ponce School of Medicine and completed his residency training at the prestigious University of Pennsylvania. He also completed an Advanced Training Course in Stem Cells in Cancer at the Ponce Health Sciences University/ Magee Research Institute consortium. He is board certified in Clinical Lipidology. Dr. Martinez holds a Master of Public Health with a concentration in Epidemiology and is fellowship trained in Biosecurity. He is the president of Xanogene Clinic, which specialized in Regenerative and Age Management Medicine. He also founded and presides over Regenera Global, a multinational corporation specializing in biotech product development, research, and clinical consulting.
Dr. Martinez is also Co-Founder of the Clinical Peptide Society, a US based professional organization aimed at educating physicians and advancing the use of peptide therapeutics. Alongside with the Age Management Medicine Group, he and his colleague have developed the world’s first Peptide Certification Program and have so far trained and educated over 400 physicians. He additionally trains physicians in other aspects of Regenerative and Age Management Medicine through his physician training portal Elite Group MD.
Dr. Martinez recently founded, alongside various colleagues the Senotherapy Network. It is the first professional organization dedicated to advancing the science and clinical applications of senolytic therapies.
Dr. Vincent Giampapa
Cellular Aging Expert & Anti-Aging Pioneer
Cellular Aging Expert & Anti-Aging Pioneer
Dr. Vincent Giampapa is Board Certified in Plastic and Reconstructive Surgery and Anti-Aging Medicine, and the Founding Director of Plastic Surgery Center International, The Giampapa Institute for Anti-Aging Medical Therapy, and the Regenerative Medicine Institute (RMI), located in Costa Rica. Dr. Giampapa believes RMI will become the global portal for stem cell therapy and advanced regenerative medicine research within the biotechnology incubator park (also slated to be a major component of RMI). Dr. Giampapa was nominated in 2014 for a Nobel Prize for his groundbreaking research into cellular restoration technology. He is a co-founder of The Academy of Anti-Aging Medicine (A4M), comprised of over 26,000 members representing over 110 nations, the first president of the Board of Anti-Aging Medicine and the founder of Healthycell, an advanced cell health nutritional supplement and Stem Bank, a blood-derived stem cell extraction and Storage Company.
Dr. Giampapa has been a keynote speaker at several international forums, most recently at the Vatican in Rome for the Second International Vatican Adult Stem Cell Conference, and the Swedish American Life Science Summit in Stockholm. He recently appeared on The Science Channel special, Stem Cell Universe with host Steven Hawking. Dr. Giampapa received an Edison Award for his development of the Healthycell nutritional supplement, as well as an A4M Science & Technology Award for his development of the BioMarker Matrix Profile—the first computer program to measure aging. He served as a consultant for NASA for the space shuttle robotic arm, and currently serves as a Medical Advisor to Jeunesse Global and Allergan Medical.
Jin-Xiong She, Ph.D.
Founder and CEO of Jinfiniti Precision Medicine, Inc.
Founder and CEO of Jinfiniti Precision Medicine, Inc.
Jin-Xiong She, Ph.D. is a Professor and Eminent Scholar and founding director of the Center for Biotechnology and Genomic Medicine at the Medical College of Georgia (MCG), Augusta University. Dr. She has almost four decades of academic research experience and published over 300 peer-reviewed scientific papers. His research focuses on the development and application of high throughput omic and bioinformatic technologies for biomarker discovery and design of novel prevention and intervention strategies for human diseases and extension of healthspan. Dr. She has extensive experience in designing and managing large-scale, longitudinal, and population-based studies.
Dr. She is the founder and CEO of Jinfiniti Precision Medicine, Inc. (JPM, www.jinfiniti.com ), which develops, and offers testing services for, longevity biomarkers. JPM’s AgingSOS™ longevity test panels include a variety of biomarkers for the major underlying causes of aging-related diseases (ARD): chronic inflammation, cellular senescence, oxidative stress and antioxidant capacity, tissue damage, protein glycation and micronutrient deficiencies (NAD and vitamin D). These biomarkers are ideal for guiding personalized nutraceuticals for prevention and management of ARD and extension of healthspan.
Dr. Edwin Lee
Founder of the Institute for Hormonal Balance
Founder of the Institute for Hormonal Balance
Dr. Edwin Lee is an endocrinologist, author and international speaker. Dr. Lee founded the Institute for Hormonal Balance, Orlando, FL in 2008, is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism, and has completed special training in Regenerative and Functional Medicine. He is a graduate of the Medical College of Pennsylvania and finished his fellowships at the University of Pittsburgh. He is the author of Feel Good Look Younger, Your Best Investment: Secrets to a Healthy Body and Mind, Your Amazing Heart, Your Awesome Brain and The Fountain of Youth with Peptides.
Dr. Lee is the lead investigator for an IRB approved senolytic study investigating the role of Dasatinib and Quercetin on the changes of the immune system, effects on the epigenetic pattern in saliva and in blood, and possible reduction of senescence. Dr. Lee has lectured on aging and senescence and reviewed the human clinical trials on senescence at a recent meeting with Clinical Peptide Society.